Clinical Trials Logo

Leukemia, B-Cell clinical trials

View clinical trials related to Leukemia, B-Cell.

Filter by:

NCT ID: NCT04747093 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

Induced-T Cell Like NK Cells for B Cell Malignancies

Start date: January 29, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Relapsed and refractory B cell malignancies show unfavorable prognosis, especially for adult patients. Now, there is no standard management for these patients. Induced-T cell-like NK cells with chimeric antigen receptor (CAR-ITNK cells) is a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of CAR-ITNK cells infusions in patients with relapsed and refractory B cell malignancies.

NCT ID: NCT04714593 Recruiting - Clinical trials for Acute Lymphocytic Leukemia, B-Cell

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

Start date: January 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-CD22 CAR-T cells for the treatment of acute B lymphocytic leukemia.

NCT ID: NCT04649983 Recruiting - Lymphoma, B-Cell Clinical Trials

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Start date: September 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.

NCT ID: NCT04648475 Recruiting - Lymphoma, B-Cell Clinical Trials

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Start date: August 25, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.

NCT ID: NCT04516551 Recruiting - B Cell Leukemia Clinical Trials

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

Start date: November 20, 2020
Phase: Phase 1
Study type: Interventional

The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time after transplantation. Nowadays there is no effective way to salvage patients in such conditions. T cells derived from healthy matched sibling or unrelated donors have not been restrained by tumor micro-environment and retain anti-leukemia ability, which makes it serve well for patients with relapsed B-ALL. So we launched a multi-center clinical trial to proved the safety and efficacy of anti-CD19 CAR-T cells for relapsed B cell ALL.

NCT ID: NCT04439721 Recruiting - Leukemia, B-cell Clinical Trials

γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse

?dT
Start date: May 1, 2020
Phase: Early Phase 1
Study type: Interventional

Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

NCT ID: NCT04271800 Recruiting - Lymphoma Clinical Trials

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Start date: December 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

NCT ID: NCT04271410 Recruiting - Leukemia Clinical Trials

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Start date: June 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

NCT ID: NCT04156243 Recruiting - B Cell Lymphoma Clinical Trials

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

Start date: February 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.

NCT ID: NCT04156178 Recruiting - B Cell Lymphoma Clinical Trials

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Start date: August 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD20-CD19 cCAR in patients with relapsed and/or refractory B cell malignancies.